CAR T-cell therapy for treating acute leukaemia

Bookmark and Share
Published: 20 Jun 2019
Views: 1293
Rating:
Save
Prof Mohamad Mohty - Saint-Antoine Hospital, Paris, France

Prof Mohamad Mohty speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the promising CAR T-cell therapy for acute leukaemia patients.

He explains that a substantial proportion of acute lymphocytic leukaemia and non-Hodgkin lymphoma patients are cured after this treatment.

Prof Mohty believes that the major issue currently faced is a lack of 'persistence' of these cells, but there are many different possibilities that can improve this.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Definitely CAR T-cells are the major breakthrough over the last few years in the field of haematology and today we are fortunate enough to have two commercially available products approved and being increasingly used for the treatment of ALL and non-Hodgkin lymphoma. What we have seen these days is that definitely we have mature results and a substantial proportion of ALL in non-Hodgkin lymphoma patients are definitely cured after these CAR T-cells. So this is wonderful news for the patient.

Initially there were some, I would say, concerns about the serious side effects of these CAR T-cells, namely the cytokine release syndrome and neurotoxicity. This is, of course, an important issue and we need to tackle it. However, we have seen awareness being increased and the management of these complications is being improved. Now people after having the proof of concept, after having hundreds of patients treated, actually the community is already moving to the next step – targeting other antigens, having dual CAR T-cells, for example in lymphoma CD19 and CD22. But also the major issue we are facing is the lack of persistence of these cells. So this is why a lot of work is still to be done and there are many different avenues to try to improve or to allow or to increase the expansion of these cells in vivo – use of cytokines, armoured CAR T-cells, the checkpoint inhibitors in combination with CAR T-cells can be of interest. We’ve seen some results in CLL where ibrutinib, for example, can help or can favour the persistence of these cells. So this is really an exciting era for investigation but definitely CAR T-cells are becoming a key component of the management of ALL and non-Hodgkin lymphoma.